Skip to main content

Fremanezumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 19, 2023.

Applies to fremanezumab: subcutaneous solution.

Serious side effects of Fremanezumab

Along with its needed effects, fremanezumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fremanezumab:

More common

Other side effects of Fremanezumab

Some side effects of fremanezumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to fremanezumab: subcutaneous solution.

General

The most commonly reported adverse reaction during clinical trials was injection site reactions.[Ref]

Local

Very common (10% or more): Injection site reactions (up to 45%)[Ref]

Injection site reactions included injection site pain, induration, erythema, and pruritus.[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity reactions

Postmarketing reports: Anaphylaxis, angioedema

Immunologic

Common (1% to 10%): Anti-Drug-Antibodies[Ref]

Frequently asked questions

References

1. EMEA. European Medicines Agency. EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid 2007.

2. Product Information. Ajovy (fremanezumab). Nephroceuticals. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.